Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
about
New Developments in Chronic Myeloid Leukemia: Implications for TherapyBiomarkers for determining the prognosis in chronic myelogenous leukemiaKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsSecondary mutations as mediators of resistance to targeted therapy in leukemiaMulticenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.New dosing schedules of dasatinib for CML and adverse event managementDasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyChronic myeloid leukemia: mechanisms of blastic transformationAssociation between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemiaKinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Loss of p53 impedes the antileukemic response to BCR-ABL inhibitionChronic myelogenous leukemia: treatment and monitoring.Monitoring response and resistance to treatment in chronic myeloid leukemia.A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinibKLF4 suppresses transformation of pre-B cells by ABL oncogenesFurther phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cellsDual tyrosine kinase inhibitors in chronic myeloid leukemia.Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.Implications of cancer stem cells in the treatment of cancer.Therapeutic use of Aldara in chronic myeloid leukemia.Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.Current practices in the management of chronic myeloid leukemia.Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.Targeted therapy in chronic myeloid leukemia.
P2860
Q26745669-1F63E935-D364-4451-B239-9FB68121AAE1Q26824660-6CD4F059-C264-4456-995B-DE721BFA98C1Q26849792-0FEA2DA1-1758-4AB0-BC6C-BBF0C82FD939Q27028181-F0D63527-17E1-4517-AF8E-318777D348D2Q28087213-8282FFD1-C8BB-4C35-BADF-9EE9A9986B0BQ29999611-37633344-8682-41CF-BB40-9FF68418808AQ30242015-5A3937A4-BC1F-4CEC-9EBF-6E20FA633A62Q30251920-857CCF92-2589-470E-A4CB-6BC59C9D4AAEQ33383407-793643D0-78E6-42C7-964A-4F580A8372E7Q33384766-3993FBC2-5B33-4114-B6F1-2256C1DDFDECQ33397085-495863F0-5DBF-4545-B07B-D0FEDED01684Q33476874-6F6F0FEE-CF38-4CB1-9C90-B90D414E91EDQ33968037-9D6BDB91-9F84-4E57-934F-95FAF40357E0Q33988398-06AEAEC7-6D3F-4363-ADE2-E2142DF4D29EQ34016866-247100F6-5C51-4A5F-93C9-31699DC16547Q34251703-D107FC04-E0E2-480A-8829-B280E17CD152Q34378360-9606B6AF-821B-4BDA-B363-DF39E4A73918Q34417824-E67615A0-0B82-4A2A-AA18-04385579CF09Q34585293-4A9D60E8-4063-45AA-A3FE-2B97A8A07C82Q34617628-8749E6AD-58FE-421C-A288-5274E7CE9C92Q34761663-A1343AFC-93BD-40B1-A6E7-7A2EA0943945Q35040972-46D11110-1AB9-4C75-B60C-7C4C1E41A306Q35615876-24F29E5F-686C-443F-B211-E69D0B922A79Q35664306-C2F5135E-8A69-4B48-86F3-D49627181F8FQ35731623-5DFA29EE-C584-42FA-8163-849880342628Q35804449-8BA61F3A-265D-4A38-85A4-455C4B0DDD77Q35849776-FD58E2CB-1487-409D-897F-0C49E6F3652AQ35998184-EE895D28-A591-4DF9-B8B7-E910F87948BCQ36240238-9003C042-28C2-44E6-9E3B-F389D2D63C98Q36265601-B3B2D053-60B4-4034-86F5-371E72F9052AQ36508969-89F5D962-8259-4EC6-9482-597133467433Q36675836-D97F4650-4BAA-499C-992D-62C726784D99Q36677482-2B2B690B-69D5-4438-9720-59C925086F5AQ36718548-F2DF0AD3-AEBE-4854-A6ED-2CFDA4A79167Q36794006-E3AAD45F-74F7-4A89-AA1C-E15C44366D96Q36802620-6D1B5815-187C-4307-91A1-A2932F446583Q36819555-247BB422-4615-4E7C-AE51-AF5720C06B41Q37026026-D8F79DCB-7363-4006-9A4B-BA737966D40BQ37028631-C52B3181-0526-49FE-B064-A2B53E392B99Q37038914-D060587A-94AA-4824-AC34-89741B0855AF
P2860
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Response and resistance in 300 ...... center: a 4.5-year follow-up.
@en
Response and resistance in 300 ...... center: a 4.5-year follow-up.
@nl
type
label
Response and resistance in 300 ...... center: a 4.5-year follow-up.
@en
Response and resistance in 300 ...... center: a 4.5-year follow-up.
@nl
prefLabel
Response and resistance in 300 ...... center: a 4.5-year follow-up.
@en
Response and resistance in 300 ...... center: a 4.5-year follow-up.
@nl
P2093
P2860
P356
P1433
P1476
Response and resistance in 300 ...... center: a 4.5-year follow-up.
@en
P2093
Birte Riehm
Kirsten Merx
Martin C Müller
Peter Paschka
Rüdiger Hehlmann
Sebastian Kreil
Tanja Lahaye
Ute Berger
Uwe Schwindel
P2860
P304
P356
10.1002/CNCR.20922
P407
P577
2005-04-01T00:00:00Z